Carlo B. Passerini-Gambacorti

Monza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 193 publications

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.

DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups.

Journal: EJHaem
Published: July 14, 2026

Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Journal: Leukemia
Published: June 24, 2026

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.

Journal: NEJM evidence
Published: May 26, 2026

Circular RNA in chronic myeloid leukemia.

Circular RNA in chronic myeloid leukemia.

Journal: Blood
Published: May 14, 2026

Author Correction: Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Author Correction: Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Journal: Nature medicine
Published: March 21, 2026

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Journal: Cancer
Published: November 16, 2025

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Journal: Haematologica
Published: November 13, 2025

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Journal: Annals of hematology
Published: July 23, 2025

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.

Journal: Leukemia & lymphoma
Published: June 23, 2025

An Uncommon Presentation of Sweet's Syndrome in Primary Myelofibrosis.

An Uncommon Presentation of Sweet's Syndrome in Primary Myelofibrosis.

Journal: Case reports in hematology
Published: June 05, 2025

Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing-Neel Syndrome.

Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing-Neel Syndrome.

Journal: American journal of hematology
Published: May 18, 2025

Correction: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Correction: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Journal: Oncogene
Published: May 02, 2025
Showing 1-12 of 193

Last Updated: 09/26/2026